{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:45:03Z","timestamp":1788223503168,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.genhosppsych.2026.04.006","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T23:15:01Z","timestamp":1776467701000},"page":"208-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Implementation and service impact of anti-amyloid therapy in a psychiatry-led dementia care program: Real-world evidence from a Japanese regional dementia center"],"prefix":"10.1016","volume":"100","author":[{"given":"Kyohei","family":"Otani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Kawabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.genhosppsych.2026.04.006_bb0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.genhosppsych.2026.04.006_bb0010","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"10248","key":"10.1016\/j.genhosppsych.2026.04.006_bb0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the lancet commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"issue":"10284","key":"10.1016\/j.genhosppsych.2026.04.006_bb0020","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.genhosppsych.2026.04.006_bb0025","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S1474-4422(23)00274-0","article-title":"Preparing for disease-modifying therapies in Alzheimer\u2019s disease","volume":"22","author":"Belder","year":"2023","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.genhosppsych.2026.04.006_bb0030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41582-024-01022-1","article-title":"Preparing for disease-modifying dementia therapies in the UK","volume":"20","author":"Cooper","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.genhosppsych.2026.04.006_bb0035","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s association research roundtable workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"10","key":"10.1016\/j.genhosppsych.2026.04.006_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70652","article-title":"Real-world lecanemab adoption in Japan 1 year after launch: insights from 311 specialists on infrastructure and reimbursement barriers","volume":"21","author":"Sato","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.genhosppsych.2026.04.006_bb0045","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.genhosppsych.2026.04.006_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.genhosppsych.2026.04.006_bb0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12888-021-03241-y","article-title":"Consultation-liaison psychiatry in Japan: a nationwide retrospective observational study","volume":"21","author":"Shinjo","year":"2021","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.genhosppsych.2026.04.006_bb0060","first-page":"3","article-title":"Differential diagnosis of dementia: a key role of general hospital psychiatry","volume":"79","author":"Funayama","year":"2025","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.genhosppsych.2026.04.006_bb0065","series-title":"New Orange plan: Comprehensive strategy for promotion of dementia measures","author":"Ministry of Health, Labour and Welfare, Japan","year":"2015"},{"issue":"3","key":"10.1016\/j.genhosppsych.2026.04.006_bb0070","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1479-8301.2011.00367.x","article-title":"Exploring strategies to alleviate caregiver burden: effects of the national long-term care insurance scheme in Japan","volume":"11","author":"Arai","year":"2011","journal-title":"Psychogeriatrics"},{"issue":"1","key":"10.1016\/j.genhosppsych.2026.04.006_bb0075","doi-asserted-by":"crossref","first-page":"67","DOI":"10.31662\/jmaj.2018-0015","article-title":"The long-term care insurance system in Japan: past, present, and future","volume":"2","author":"Iwagami","year":"2019","journal-title":"JMA J"},{"issue":"2","key":"10.1016\/j.genhosppsych.2026.04.006_bb0080","article-title":"Preliminary real-world trends in outpatient revenue following disease-modifying therapy implementation in general hospital psychiatry in Japan","volume":"5","author":"Otani","year":"2026","journal-title":"PCN Rep"},{"issue":"4","key":"10.1016\/j.genhosppsych.2026.04.006_bb0085","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"6","key":"10.1016\/j.genhosppsych.2026.04.006_bb0090","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the international working group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2026.04.006_bb0095","doi-asserted-by":"crossref","first-page":"e-1","DOI":"10.1016\/j.jalz.2013.01.002","article-title":"Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the Alzheimer\u2019s association","volume":"9","author":"Johnson","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"13","key":"10.1016\/j.genhosppsych.2026.04.006_bb0100","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.genhosppsych.2026.04.006_bb0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10488-010-0319-7","article-title":"Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda","volume":"38","author":"Proctor","year":"2011","journal-title":"Admin Pol Ment Health"},{"key":"10.1016\/j.genhosppsych.2026.04.006_bb0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13012-015-0209-1","article-title":"A refined compilation of implementation strategies: results from the ERIC project","volume":"10","author":"Powell","year":"2015","journal-title":"Implement Sci"},{"key":"10.1016\/j.genhosppsych.2026.04.006_bb0115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1748-5908-4-50","article-title":"Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science","volume":"4","author":"Damschroder","year":"2009","journal-title":"Implement Sci"},{"key":"10.1016\/j.genhosppsych.2026.04.006_bb0120","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13012-015-0242-0","article-title":"Making sense of implementation theories, models and frameworks","volume":"10","author":"Nilsen","year":"2015","journal-title":"Implement Sci"},{"issue":"4","key":"10.1016\/j.genhosppsych.2026.04.006_bb0125","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.0887-378X.2004.00325.x","article-title":"Diffusion of innovations in service organizations: systematic review and recommendations","volume":"82","author":"Greenhalgh","year":"2004","journal-title":"Milbank Q"},{"key":"10.1016\/j.genhosppsych.2026.04.006_bb0130","article-title":"The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer\u2019s disease: an EADC-EC viewpoint","volume":"29","author":"J\u00f6nsson","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"3","key":"10.1016\/j.genhosppsych.2026.04.006_bb0135","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40120-022-00373-5","article-title":"The potential economic value of Lecanemab in patients with early Alzheimer\u2019s disease using simulation modeling","volume":"11","author":"Tahami Monfared","year":"2022","journal-title":"Neurol Ther"},{"issue":"4","key":"10.1016\/j.genhosppsych.2026.04.006_bb0140","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40120-023-00492-7","article-title":"Predicting the societal value of lecanemab in early Alzheimer\u2019s disease in Japan: a patient-level simulation","volume":"12","author":"Igarashi","year":"2023","journal-title":"Neurol Ther"},{"issue":"7","key":"10.1016\/j.genhosppsych.2026.04.006_bb0145","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209218","article-title":"Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer disease","volume":"102","author":"Nguyen","year":"2024","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.genhosppsych.2026.04.006_bb0150","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40273-025-01527-7","article-title":"The cost-effective price of lecanemab for patients with early Alzheimer\u2019s disease in Sweden","volume":"43","author":"Xia","year":"2025","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.genhosppsych.2026.04.006_bb0155","doi-asserted-by":"crossref","first-page":"400","DOI":"10.5770\/cgj.28.888","article-title":"Anti-amyloid therapies for Alzheimer\u2019s disease: not the way forward","volume":"28","author":"Bocti","year":"2025","journal-title":"Can Geriatr J"},{"issue":"1","key":"10.1016\/j.genhosppsych.2026.04.006_bb0160","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","article-title":"Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","volume":"14","author":"McDade","year":"2022","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"18","key":"10.1016\/j.genhosppsych.2026.04.006_bb0165","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.genhosppsych.2026.04.006_bb0170","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.genhosppsych.2026.04.006_bb0175","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"issue":"12","key":"10.1016\/j.genhosppsych.2026.04.006_bb0180","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/jamaneurol.2024.3379","article-title":"Collaborative dementia care during the new therapeutic era","volume":"81","author":"Possin","year":"2024","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.genhosppsych.2026.04.006_bb0185","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/jnnp-2024-333468","article-title":"Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer\u2019s disease","volume":"95","author":"Dobson","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.genhosppsych.2026.04.006_bb0190","doi-asserted-by":"crossref","first-page":"265","DOI":"10.14283\/jpad.2024.37","article-title":"Anti-amyloid therapies for Alzheimer\u2019s disease: an alzheimer europe position paper and call to action","volume":"11","author":"Bradshaw","year":"2024","journal-title":"J Prev Alzheimers Dis"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834326000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834326000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:40:46Z","timestamp":1787380846000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834326000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":38,"alternative-id":["S0163834326000770"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2026.04.006","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementation and service impact of anti-amyloid therapy in a psychiatry-led dementia care program: Real-world evidence from a Japanese regional dementia center","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2026.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}